[1] Jiang Z, Zeng G, Dai H, et al. Global, regional and national burden of liver cancer 1990-2021: a systematic analysis of the global burden of disease study 2021[J]. BMC Public Health, 2025, 25(1): 931.
[2] Wu C, Targher G, Byrne C D, et al. Global, regional, and national burden of primary liver cancer attributable to metabolic risks: an analysis of the global burden of disease study 1990-2021[J]. Am J Gastroenterol, 2025.
[3] Guo Q, Zhu X, Beeraka N M, et al. Projected epidemiological trends and burden of liver cancer by 2040 based on GBD, CI5plus, and WHO data[J]. Sci Rep, 2024, 14(1): 28131.
[4] Qiu S, Cai J, Yang Z, et al. Trends in hepatocellular carcinoma mortality rates in the US and projections through 2040[J]. JAMA Netw Open, 2024, 7(11): e2445525.
[5] Lee R M, Gamboa A C, Turgeon M K, et al. The evolving landscape of hepatocellular carcinoma : a US safety net collaborative analysis of etiology of cirrhosis[J]. Am Surg, 2020, 86(7): 865-872.
[6] Eghbali S, Heumann T R. Next-generation immunotherapy for hepatocellular carcinoma: mechanisms of resistance and novel treatment approaches[J]. Cancers (Basel), 2025, 17(2).
[7] Chen Y, Hu H, Yuan X, et al. Advances in immune checkpoint inhibitors for advanced hepatocellular carcinoma[J]. Front Immunol, 2022, 13: 896752.
[8] Ouyang T, Kan X, Zheng C. Immune checkpoint inhibitors for advanced hepatocellular carcinoma: ,monotherapies and combined therapies[J]. Front Oncol, 2022, 12: 898964.
[9] Chan L L, Chan S L. Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma[J]. Expert Opin Emerg Drugs, 2021, 26(1): 39-52.
[10] Vogel A, Chan S L, Dawson L A, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up[J]. Ann Oncol, 2025, 36(5): 491-506.
[11] Cheng W, Kang K, Zhao A, et al. Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer[J]. J Hematol Oncol, 2024, 17(1): 54.
[12] 中华人民共和国国家卫生健康委员会医政司. 原发性肝癌诊疗指南(2024年版)[J]. 中华肝脏病杂志, 2024, 32(7): 581-630.
[13] D′Angelo A, Sobhani N, Bagby S, et al. Cabozantinib as a second-line treatment option in hepatocellular carcinoma[J]. Expert Rev Clin Pharmacol, 2020, 13(6): 623-629.
[14] Wan Y, Zhu H. Regorafenib combined with sintilimab as second-line treatment for advanced HCC patient: a case report[J]. Front Oncol, 2023, 13: 1256137.
[15] Bangaru S, Marrero J A, Singal A G. Review article: new therapeutic interventions for advanced hepatocellular carcinoma[J]. Aliment Pharmacol Ther, 2020, 51(1): 78-89.
[16] Zheng S S, Wu J F, Zhang Z Z, et al. Efficacy and safety of ipilimumab plus anti-PD-1/PD-L1 antibodies combination therapy in advanced hepatocellular carcinoma patients progressing after multiple lines of treatment: a retrospective multicenter study[J]. J Hepatocell Carcinoma, 2025, 12: 527-537.
[17] Gordan J D, Kennedy E B, Abou-Alfa G K, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO Guideline Update[J]. J Clin Oncol, 2024, 42(15): 1830-1850.
[18] Hiraoka A, Kumada T, Hatanaka T, et al. Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression[J]. Hepatol Res, 2021, 51(8): 880-889.
[19] Memon K, Kulik L, Lewandowski R J, et al. Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression[J]. J Hepatol, 2013, 58(1): 73-80.
[20] Abou-Alfa G K, Amadori D, Santoro A, et al. Safety and efficacy of sorafenib in patients with hepatocellular carcinoma (HCC) and Child-Pugh A versus B cirrhosis[J]. Gastrointest Cancer Res, 2011, 4(2): 40-44.
[21] Sarmento-Ribeiro A B, Scorilas A, Gon?alves A C, et al. The emergence of drug resistance to targeted cancer therapies: clinical evidence[J]. Drug Resist Updat, 2019, 47: 100646.
[22] Huang C, Zhang C, Li J, et al. Targeting p38γ synergistically enhances sorafenib-induced cytotoxicity in hepatocellular carcinoma[J]. Cell Biol Toxicol, 2025, 41(1): 35.
[23] Xian F, Wu C, Zhang G, et al. Efficacy and safety of immune checkpoint inhibitors combined anti-angiogenic therapy in patients with unresectable hepatocellular carcinoma: a meta-analysis[J]. Medicine (Baltimore), 2022, 101(44): e31479.
[24] Zhong Y, Huo H, Dai S, et al. Efficacy and safety of immune checkpoint inhibitors-combined antiangiogenic drugs in the treatment of hepatocellular carcinoma: a systematic review and meta analysis[J]. Front Oncol, 2022, 12: 964779.
[25] Pinato D J, Marron T U, Mishra-Kalyani P S, et al. Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice[J]. Eur J Cancer, 2021, 157: 140-152.
[26] Vincenzi B, Santini D, Russo A, et al. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib[J]. Oncologist, 2010, 15(1): 85-92. |
